0001415889-24-008636.txt : 20240319
0001415889-24-008636.hdr.sgml : 20240319
20240319181837
ACCESSION NUMBER: 0001415889-24-008636
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240315
FILED AS OF DATE: 20240319
DATE AS OF CHANGE: 20240319
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Swirsky Douglas J
CENTRAL INDEX KEY: 0001375884
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40674
FILM NUMBER: 24765471
MAIL ADDRESS:
STREET 1: C/O REXAHN PHARMACEUTICALS, INC.
STREET 2: 15245 SHADY GROVE ROAD SUITE 455
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MAXCYTE, INC.
CENTRAL INDEX KEY: 0001287098
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 522210438
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9713 KEY WEST AVENUE,
STREET 2: SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-517-5556
MAIL ADDRESS:
STREET 1: 9713 KEY WEST AVENUE,
STREET 2: SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: MAXCYTE INC
DATE OF NAME CHANGE: 20040415
4
1
form4-03192024_100330.xml
X0508
4
2024-03-15
0001287098
MAXCYTE, INC.
MXCT
0001375884
Swirsky Douglas J
C/O MAXCYTE, INC.
9713 KEY WEST AVENUE, SUITE 400
ROCKVILLE
MD
20850
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Common Stock
2024-03-15
4
A
0
81250
0
A
81250
D
Employee Stock Option (right to buy)
4.31
2024-03-15
4
A
0
225000
0
A
2034-03-14
Common Stock
225000
225000
D
These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 15, 2025, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Twenty-five percent (25%) of the shares underlying this option shall vest on March 15, 2025, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
/s/ Katie Kazem, Attorney-in-Fact
2024-03-19